<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04518254</url>
  </required_header>
  <id_info>
    <org_study_id>2018PPRC25</org_study_id>
    <secondary_id>2019-A03194-53</secondary_id>
    <nct_id>NCT04518254</nct_id>
  </id_info>
  <brief_title>Contribution of L-Tyrosine to Human Decision Making in Stressful Situations</brief_title>
  <acronym>TYRO-STRESS</acronym>
  <official_title>Contribution of L-Tyrosine to Human Decision Making in Stressful Situations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Direction Centrale du Service de Santé des Armées</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Direction Centrale du Service de Santé des Armées</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      L-tyrosine is a chemical precursor of dopamine. Under specific conditions, tyrosine&#xD;
      administration can increase brain dopamine levels and therefore several studies have explored&#xD;
      whether tyrosine supplementation can have a beneficial effect on cognitive and behavioural&#xD;
      performance that is dependent on dopaminergic function. However, the effects of tyrosine&#xD;
      supplementation are mixed: some studies show positive effects while others do not. Stress&#xD;
      leads to an increase in dopaminergic activity and turnover in the brain, resulting in a&#xD;
      decrease in brain dopamine levels. We propose to study the contribution of tyrosine to&#xD;
      decision making and more particularly to the processes of response selection (mediated by the&#xD;
      prefrontal cortex and under the influence of the dopaminergic system) in stressful&#xD;
      situations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>The study is composed of 4 arms:&#xD;
Tyrosine treatment without stress exposure&#xD;
Tyrosine treatment with stress exposure&#xD;
Placebo treatment without stress exposure&#xD;
Placebo treatment with stress exposure&#xD;
Every participants will participate in the 4 arms in a random order.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>The pharmacist, carrying out the packaging and labelling of the treatment units, will ensure the blinding. Neither the participant nor the investigator will know what treatment is being administered.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Reaction Time</measure>
    <time_frame>At day 9 (9 days after enrollment)</time_frame>
    <description>Reaction Time at the cognitive tasks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of incorrect responses</measure>
    <time_frame>At day 9</time_frame>
    <description>Number of incorrect responses at the cognitive tasks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Error negativity</measure>
    <time_frame>At day 9</time_frame>
    <description>Error negativity on motor evoked potentials (measured by EMG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation coefficient between anxiety level and tyrosinemia</measure>
    <time_frame>At day 9</time_frame>
    <description>Correlation coefficient between anxiety level (measured by anxiety scale) and tyrosinemia (measured in blood sample)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation coefficient between anxiety level and plasma tyrosine</measure>
    <time_frame>At day 9</time_frame>
    <description>Correlation coefficient between anxiety level (measured by anxiety scale) and plasma tyrosine (measured in blood sample)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation coefficient between cortisolaemia and melatoninaemia</measure>
    <time_frame>At day 9</time_frame>
    <description>Correlation coefficient between cortisolaemia and melatoninaemia (measured in blood sample)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Stress, Psychological</condition>
  <arm_group>
    <arm_group_label>Tyrosine - Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 similar visits (day 0, day 3, day 6, day 9): Administration of L-tyrosine No stress exposure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tyrosine - Stress</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 similar visits (day 0, day 3, day 6, day 9): Administration of L-tyrosine Stress exposure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 similar visits (day 0, day 3, day 6, day 9): Administration of Placebo No stress exposure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - Stress</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 similar visits (day 0, day 3, day 6, day 9): Administration of Placebo Stress exposure</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood collection</intervention_name>
    <description>A blood sample will be collected before and after treatment administration</description>
    <arm_group_label>Placebo - Stress</arm_group_label>
    <arm_group_label>Placebo - Test</arm_group_label>
    <arm_group_label>Tyrosine - Stress</arm_group_label>
    <arm_group_label>Tyrosine - Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-Tyrosine 500 Mg</intervention_name>
    <description>The participants will be administered 4 capsules of L-Tyrosine 500 mg per oral route</description>
    <arm_group_label>Tyrosine - Stress</arm_group_label>
    <arm_group_label>Tyrosine - Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The participants will be administered 4 capsules of Lactose 500 mg (placebo) per oral route</description>
    <arm_group_label>Placebo - Stress</arm_group_label>
    <arm_group_label>Placebo - Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive tasks</intervention_name>
    <description>The participants will perform cognitive decision-making tasks: Simon task and masking task after treatment administration</description>
    <arm_group_label>Placebo - Stress</arm_group_label>
    <arm_group_label>Placebo - Test</arm_group_label>
    <arm_group_label>Tyrosine - Stress</arm_group_label>
    <arm_group_label>Tyrosine - Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Stress exposure</intervention_name>
    <description>Unpleasant but not painful skin stimulations will be administered to the participants at variable intervals on the left leg during the cognitive tasks</description>
    <arm_group_label>Placebo - Stress</arm_group_label>
    <arm_group_label>Tyrosine - Stress</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Anxiety scale</intervention_name>
    <description>Spielberger's State Trait Anxiety Inventory (STAI) will be filled by the participants before and after cognitive tasks</description>
    <arm_group_label>Placebo - Stress</arm_group_label>
    <arm_group_label>Placebo - Test</arm_group_label>
    <arm_group_label>Tyrosine - Stress</arm_group_label>
    <arm_group_label>Tyrosine - Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Electromyography (EMG)</intervention_name>
    <description>Electromyography measurements will be performed during cognitive tasks.</description>
    <arm_group_label>Placebo - Stress</arm_group_label>
    <arm_group_label>Placebo - Test</arm_group_label>
    <arm_group_label>Tyrosine - Stress</arm_group_label>
    <arm_group_label>Tyrosine - Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Electroencephalography (EEG)</intervention_name>
    <description>Electroencephalography measurements will be performed during cognitive tasks.</description>
    <arm_group_label>Placebo - Stress</arm_group_label>
    <arm_group_label>Placebo - Test</arm_group_label>
    <arm_group_label>Tyrosine - Stress</arm_group_label>
    <arm_group_label>Tyrosine - Test</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  From 18 to 65 years of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Tyrosine intake within the previous 15 days&#xD;
&#xD;
          -  History of neurological or psychiatric disorder&#xD;
&#xD;
          -  History of nephrological or endocrine disorder or liver failure&#xD;
&#xD;
          -  Hereditary tyrosinemia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Céline RAMDANI, MD, PhD</last_name>
    <phone>178651265</phone>
    <phone_ext>+33</phone_ext>
    <email>celine.ramdani@intradef.gouv.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut de Recherche Biomédicale des Armées</name>
      <address>
        <city>Brétigny-sur-Orge</city>
        <zip>91223</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Céline RAMDANI, MD, PhD</last_name>
      <phone>178651265</phone>
      <phone_ext>+33</phone_ext>
      <email>celine.ramdani@intradef.gouv.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 15, 2020</study_first_submitted>
  <study_first_submitted_qc>August 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2020</study_first_posted>
  <last_update_submitted>July 6, 2021</last_update_submitted>
  <last_update_submitted_qc>July 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>L-tyrosine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stress, Psychological</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

